TransCode Therapeutics Announces Pricing of $8 Million Public Offering
25. September 2023 20:01 ET
|
TransCode Therapeutics, Inc.
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
25. September 2023 08:30 ET
|
TransCode Therapeutics, Inc.
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today...
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
23. August 2023 08:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
14. August 2023 16:45 ET
|
TransCode Therapeutics, Inc.
BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
31. Juli 2023 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today...
TransCode Therapeutics CEO Letter to Shareholders
05. Juli 2023 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, July 05, 2023 (GLOBE NEWSWIRE) -- Dear TransCode Therapeutics Shareholders, I want to express the optimism that permeates the management, board, and staff of TransCode as we navigate the...
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
22. Juni 2023 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today...
TransCode Therapeutics Announces Closing of $7 Million Public Offering
09. Juni 2023 16:05 ET
|
TransCode Therapeutics, Inc.
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
06. Juni 2023 17:29 ET
|
TransCode Therapeutics, Inc.
BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
06. Juni 2023 16:01 ET
|
TransCode Therapeutics, Inc.
BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat...